Clarifyingcomplexities Of Expandingtreatmentoptionsfor Advancedandearly-Stage Hr+/Her2- Breastcancer

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancer

PeerView Oncology

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

PeerView Oncology

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal

PeerView Oncology

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

Management of premenopausal HR+/HER2- breast cancer with micro-metastasis

Key challenge associated with the management of HR+/HER2- breast cancer

Considering Treatment for HER2-Negative Breast Cancer

Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BC

Personalizing Treatment Decisions in HER2-Altered Breast Cancer

PeerView Oncology

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

PeerView Oncology

Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in HR+ Breast Cancer

PeerView Oncology

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

European Society for Medical Oncology (ESMO)

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

CDK4/6 inhibitors in early stage HR+/HER2- disease

HER2 Positive Breast Cancer: Everything You Must Know

Breast Cancer School for Patients

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MD

Living Beyond Breast Cancer